|
Dermatitis, Atopic
|
0.700 |
Biomarker
|
disease |
BEFREE |
It has been recently shown that human IL-18 plays a role in atopic dermatitis (AD) by enhancing IL-4 and IL-13 production and by stimulating the synthesis of IgE.
|
17517100 |
2007 |
|
Dermatitis, Atopic
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
These data demonstrate that acute AD skin lesions are associated with an increased expression of IL-13 mRNA.
|
8765838 |
1996 |
|
Dermatitis, Atopic
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Dermal transgenic expression of IL-13 causes an AD-like phenotype with fibrosis and increased TSLP.
|
21576506 |
2011 |
|
Dermatitis, Atopic
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to test the IL13 p.R130Q and c.1-1111C>T variants in children with atopic dermatitis (AD) for associations with total serum IgE and early sensitization to common food and inhalant allergens and with asthma.
|
19220774 |
2009 |
|
Dermatitis, Atopic
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
In this study, it is shown that Bcl-3 is inducible by the Th2 cytokines IL-4 and IL-13 and is overexpressed in lesional skin of atopic dermatitis (AD) patients.
|
19282837 |
2009 |
|
Dermatitis, Atopic
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We also replicated the associations of the FLG, C11orf30, TMEM232-SLC25A46, TNFRSF6B-ZGPAT, OVOL1, ACTL9 and KIF3A-IL13 loci that were previously reported in GWAS of European and Chinese individuals and a meta-analysis of GWAS for atopic dermatitis.
|
23042114 |
2012 |
|
Dermatitis, Atopic
|
0.700 |
Biomarker
|
disease |
BEFREE |
Localization of interleukin-13 gene-expressing cells in tuberculin reactions and lesional skin from patients with atopic dermatitis.
|
10219773 |
1999 |
|
Dermatitis, Atopic
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
IL-31 expression correlates with the expression of IL-4 and IL-13 and is associated with atopic dermatitis in humans, indicating that IL-31 is involved in Th2-mediated skin inflammation.
|
22539792 |
2012 |
|
Dermatitis, Atopic
|
0.700 |
Biomarker
|
disease |
BEFREE |
Human keratinocyte cell line (HaCa T) was stimulated with IL-4, IL-13, and TNF-α to synthesize and secrete thymic stromal lymphopoietin (TSLP), an important cytokine of immunopathogenesis in atopic dermatitis.
|
26419317 |
2016 |
|
Dermatitis, Atopic
|
0.700 |
Biomarker
|
disease |
BEFREE |
Development of antagonistic antibody (Ab) against interleukin-4 receptor alpha (IL-4Rα) subunit of IL-4/IL-13 receptors is a promising therapeutic strategy for T helper 2 (T<sub>H</sub>2)-mediated allergic diseases such as asthma and atopic dermatitis.
|
31123339 |
2019 |
|
Dermatitis, Atopic
|
0.700 |
Biomarker
|
disease |
BEFREE |
The first highly effective mAb for AD, dupilumab, targets the IL-4/IL-13 receptor and was approved in early 2017 in the United States for moderate-to-severe adult AD.
|
28887947 |
2017 |
|
Dermatitis, Atopic
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
An increase in IL-13 expression may regulate the in vivo synthesis of IgE in patients with AD.
|
9158100 |
1997 |
|
Dermatitis, Atopic
|
0.700 |
Biomarker
|
disease |
BEFREE |
Having a dog in infancy is associated with higher IL-10 and IL-13 cytokine secretion profiles and reduced allergic sensitization and atopic dermatitis.
|
14767447 |
2004 |
|
Dermatitis, Atopic
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
We also investigated the inhibitory capacity of WIKIM30 on the development of 2,4-dinitrochlorobenzene-induced atopic dermatitis (AD), a Th2-dominant allergic disease in mice.Oral administration of <i>L. sakei</i> WIKIM30 significantly reduced AD-like skin lesions and serum immunoglobulin E and IL-4 levels while decreasing the number of CD4<sup>+</sup> T cells and B cells and the levels of Th2 cytokines (IL-4, IL-5, and IL-13) in peripheral lymph nodes and enhancing Treg differentiation and IL-10 secretion in mesenteric lymph nodes.
|
30154801 |
2018 |
|
Dermatitis, Atopic
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, serum levels of interleukin-13 were significantly increased in patients with intrinsic atopic dermatitis.
|
12406333 |
2002 |
|
Dermatitis, Atopic
|
0.700 |
Biomarker
|
disease |
BEFREE |
We examined the relationship between these single nucleotide polymorphisms and PHA-induced cytokine (IL-5, IL-10, IL-13, and IFN-gamma) response profiles at birth and at year 1, respiratory syncytial virus-induced wheezing and atopic dermatitis in the first year of life, and total IgE levels, peripheral blood eosinophil counts, and allergic sensitization at age 1 year.
|
15007355 |
2004 |
|
Dermatitis, Atopic
|
0.700 |
Biomarker
|
disease |
BEFREE |
Notably, SCCAs are induced by IL-4 and IL-13, vital Th2 cytokines that play important roles in AD etiology.
|
31378660 |
2019 |
|
Dermatitis, Atopic
|
0.700 |
Biomarker
|
disease |
BEFREE |
Dupilumab, a fully human monoclonal antibody targeting the interleukin (IL)-4 receptor α, thereby blocking the IL-4 and IL-13 pathway, is one of the first biologics that has been developed for AD.
|
30181845 |
2018 |
|
Dermatitis, Atopic
|
0.700 |
AlteredExpression
|
disease |
LHGDN |
Upregulation of IL-13 mRNA in subacute and chronic lesions of atopic dermatitis along with scant expression of IL-4 mRNA suggest that IL-13 is a crucial cytokine in lesional skin.
|
15014952 |
2004 |
|
Dermatitis, Atopic
|
0.700 |
Biomarker
|
disease |
BEFREE |
Atopic eczema is characterized by Th2-dominant immunity with the cytokine interleukin 13 and the transcription factor GATA binding protein 3 playing a critical role.
|
18410415 |
2008 |
|
Dermatitis, Atopic
|
0.700 |
Biomarker
|
disease |
BEFREE |
The multifaceted roles of IL-4 and IL-13 in allergic disease development make IL-4Rα an attractive target for treatment strategies, and a neutralizing monoclonal antibody which antagonizes the effects of both IL-4 and IL-13 by blocking the interaction site found in the IL-4 receptor subunit α (IL-4Rα) has been successfully used to treat patients with moderate-to-severe AD.
|
31596502 |
2020 |
|
Dermatitis, Atopic
|
0.700 |
Biomarker
|
disease |
BEFREE |
In addition, reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) results demonstrated that the mRNA expression of tumor necrosis factor (TNF)‑α, interferon (IFN)‑γ, interleukin (IL)‑4, IL‑13, IL‑31 and IL‑17A was reduced in ear skin following AXE administration in AD mice.
|
28990098 |
2017 |
|
Dermatitis, Atopic
|
0.700 |
Biomarker
|
disease |
BEFREE |
Seventy-eighty patients with ocular AD and 282 healthy control subjects were enrolled in an investigation of the association between the atopy-related genes (FCERB, IL13, and IFNGR1) and ocular AD.
|
17251453 |
2007 |
|
Dermatitis, Atopic
|
0.700 |
Biomarker
|
disease |
BEFREE |
Human IL-18 is an inflammatory cytokine that plays a role in atopic diseases, such as atopic eczema (AE), by enhancing IL-4 and IL-13 production and stimulating the synthesis of IgE.
|
15806006 |
2005 |
|
Dermatitis, Atopic
|
0.700 |
Biomarker
|
disease |
BEFREE |
Relevant literature concerning novel therapeutics for AD beyond targeted monoclonal antibodies antagonizing selectively interleukin (IL)-4 or IL-13 was obtained from a PubMed and clinicaltrials.gov search and summarized.
|
31622669 |
2020 |